Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Options:
A: Arm Label: BI 10773 dose plus metformin; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Glimepiride 1-4 mg plus metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 dose plus metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride 1-4 mg plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Glimepiride 1-4 mg plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 dose plus metformin
B: Arm Label: voglibose 0.2 mg three times a day (TID); Type: ACTIVE_COMPARATOR; Interventions: Drug: voglibose | Arm Label: BI 1356 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 1356 | Arm Label: BI 1356 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 1356 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: voglibose placebo, Drug: BI 1356 placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 low dose | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 high dose | Intervention Type: DRUG; Name: voglibose placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BI 1356 placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: voglibose; Assigned to Arm(s): voglibose 0.2 mg three times a day (TID)
C: Arm Label: linagliptin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin 5 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride

Answer: C